{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T16:24:45Z","timestamp":1772382285782,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T00:00:00Z","timestamp":1702684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T00:00:00Z","timestamp":1702684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Jiangsu Recbio Technology Co., Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s40121-023-00896-w","type":"journal-article","created":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T12:01:47Z","timestamp":1702728107000},"page":"57-78","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety and Immunogenicity of a Recombinant Two-Component SARS-CoV-2 Protein Vaccine: Randomized, Double-Blind, Placebo-Controlled Phase\u00a0I and Phase\u00a0II Studies"],"prefix":"10.1007","volume":"13","author":[{"given":"Chris","family":"Wynne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abundio","family":"Balgos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louie","family":"Tirador","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjuli May","family":"Jaen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zijing","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingshuang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rendu","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaping","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenrong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunxue","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengcai","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,16]]},"reference":[{"key":"896_CR1","unstructured":"World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. https:\/\/covid19.who.int\/. Accessed 30 May 2023."},{"issue":"6","key":"896_CR2","first-page":"321","volume":"39","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Zhang W. 2019 novel coronavirus variants: current status, trends and countermeasures. Chin J Infect Dis. 2021;39(6):321\u20134.","journal-title":"Chin J Infect Dis"},{"issue":"24","key":"896_CR3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114228","volume":"385","author":"Y Goldberg","year":"2021","unstructured":"Goldberg Y, Mandel M, Bar-On YM, et al. Waning immunity after the BNT162b2 vaccine in Israel. N Engl J Med. 2021;385(24):e85. https:\/\/doi.org\/10.1056\/NEJMoa2114228.","journal-title":"N Engl J Med"},{"issue":"14","key":"896_CR4","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1056\/NEJMc2112981","volume":"385","author":"J Keehner","year":"2021","unstructured":"Keehner J, Horton LE, Binkin NJ, et al. Resurgence of SARS-CoV-2 infection in a highly vaccinated health system workforce. N Engl J Med. 2021;385(14):1330\u20132. https:\/\/doi.org\/10.1056\/NEJMc2112981.","journal-title":"N Engl J Med"},{"issue":"8","key":"896_CR5","doi-asserted-by":"publisher","first-page":"nwab053","DOI":"10.1093\/nsr\/nwab053","volume":"8","author":"L Zhang","year":"2021","unstructured":"Zhang L, Cao L, Gao XS, et al. A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2. Natl Sci Rev. 2021;8(8):nwab053. https:\/\/doi.org\/10.1093\/nsr\/nwab053.","journal-title":"Natl Sci Rev"},{"key":"896_CR6","doi-asserted-by":"publisher","unstructured":"Yu J, Yao W, Hu Y, et al. A trimeric NTD and RBD SARS-CoV-2 subunit vaccine induced protective immunity in CAG-hACE2 transgenic mice and rhesus macaques. bioRxiv. 2021:2021.11.03.467182. https:\/\/doi.org\/10.1101\/2021.11.03.467182.","DOI":"10.1101\/2021.11.03.467182"},{"key":"896_CR7","unstructured":"Law B, Sturkenboom  M. Safety platform for emergency vaccines-d2.3 priority list of\nadverse events of special interest: COVID-19. https:\/\/www.regione.marche.it\/portals\/3\/farmaceutica\/SPEAC_D2.3_V2.0_COVID-19_20200525_public.pdf. Accessed 20 June 2023"},{"key":"896_CR8","unstructured":"FDA. Food and drug administration guidance document: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/toxicitygrading-scale-healthy-adult-and-adolescent-volunteers-enrolled-preventive-vaccine-clinical. Accessed 25 June 2023."},{"issue":"23","key":"896_CR9","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1016\/j.vaccine.2019.04.048","volume":"37","author":"C Cohet","year":"2019","unstructured":"Cohet C, van der Most R, Bauchau V, et al. Safety of AS03-adjuvanted influenza vaccines: a review of the evidence. Vaccine. 2019;37(23):3006\u201321. https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.048.","journal-title":"Vaccine"},{"issue":"5","key":"896_CR10","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/s1473-3099(21)00764-7","volume":"22","author":"S Sridhar","year":"2022","unstructured":"Sridhar S, Joaquin A, Bonaparte MI, et al. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase\u00a02, randomised, dose-finding, multicentre study. Lancet Infect Dis. 2022;22(5):636\u201348. https:\/\/doi.org\/10.1016\/s1473-3099(21)00764-7.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"896_CR11","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41541-022-00561-2","volume":"7","author":"N Charland","year":"2022","unstructured":"Charland N, Gobeil P, Pillet S, et al. Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in adults with and without comorbidities. NPJ Vaccines. 2022;7(1):142. https:\/\/doi.org\/10.1038\/s41541-022-00561-2.","journal-title":"NPJ Vaccines"},{"issue":"2","key":"896_CR12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41577-020-00480-0","volume":"21","author":"L Dai","year":"2021","unstructured":"Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol. 2021;21(2):73\u201382. https:\/\/doi.org\/10.1038\/s41577-020-00480-0.","journal-title":"Nat Rev Immunol"},{"issue":"10275","key":"896_CR13","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/s0140-6736(21)00241-5","volume":"397","author":"P Richmond","year":"2021","unstructured":"Richmond P, Hatchuel L, Dong M, et al. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase\u00a01, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397(10275):682\u201394. https:\/\/doi.org\/10.1016\/s0140-6736(21)00241-5.","journal-title":"Lancet"},{"issue":"12","key":"896_CR14","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/s2213-2600(21)00402-1","volume":"9","author":"SM Hsieh","year":"2021","unstructured":"Hsieh SM, Liu MC, Chen YH, et al. Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase\u00a02 trial in Taiwan. Lancet Respir Med. 2021;9(12):1396\u2013406. https:\/\/doi.org\/10.1016\/s2213-2600(21)00402-1.","journal-title":"Lancet Respir Med"},{"key":"896_CR15","doi-asserted-by":"publisher","unstructured":"Kung Y-A, Huang C-G, Huang S-Y, et al. Antibody titers measured by commercial assays are correlated with neutralizing antibody titers calibrated by international standards. medRxiv. 2021:2021.07.16.21260618. https:\/\/doi.org\/10.1101\/2021.07.16.21260618.","DOI":"10.1101\/2021.07.16.21260618"},{"issue":"24","key":"896_CR16","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1016\/j.vaccine.2019.04.055","volume":"37","author":"S Shi","year":"2019","unstructured":"Shi S, Zhu H, Xia X, Liang Z, Ma X, Sun B. Vaccine adjuvants: understanding the structure and mechanism of adjuvanticity. Vaccine. 2019;37(24):3167\u201378. https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.055.","journal-title":"Vaccine"},{"issue":"1","key":"896_CR17","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1038\/s41598-023-27698-x","volume":"13","author":"JN Bhiman","year":"2023","unstructured":"Bhiman JN, Richardson SI, Lambson BE, et al. Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages. Sci Rep. 2023;13(1):1222. https:\/\/doi.org\/10.1038\/s41598-023-27698-x.","journal-title":"Sci Rep"},{"issue":"3","key":"896_CR18","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1056\/NEJMc2206900","volume":"387","author":"X Zhao","year":"2022","unstructured":"Zhao X, Zhang R, Qiao S, et al. Omicron SARS-CoV-2 neutralization from inactivated and ZF2001 vaccines. N Engl J Med. 2022;387(3):277\u201380. https:\/\/doi.org\/10.1056\/NEJMc2206900.","journal-title":"N Engl J Med"},{"issue":"3","key":"896_CR19","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41591-022-01704-7","volume":"28","author":"SMS Cheng","year":"2022","unstructured":"Cheng SMS, Mok CKP, Leung YWY, et al. Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination. Nat Med. 2022;28(3):486\u20139. https:\/\/doi.org\/10.1038\/s41591-022-01704-7.","journal-title":"Nat Med"},{"issue":"1","key":"896_CR20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12916-022-02249-9","volume":"20","author":"X Chen","year":"2022","unstructured":"Chen X, Wang W, Chen X, et al. Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint. BMC Med. 2022;20(1):36. https:\/\/doi.org\/10.1186\/s12916-022-02249-9.","journal-title":"BMC Med"},{"key":"896_CR21","unstructured":"Jacqueline M. Miller MD FAAP. mRNA-1273 clinical development program. https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2020-08\/COVID-02-Miller-508.pdf. Accessed Aug 26, 2020."},{"issue":"7868","key":"896_CR22","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41586-021-03653-6","volume":"595","author":"U Sahin","year":"2021","unstructured":"Sahin U, Muik A, Vogler I, et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T\u00a0cells in humans. Nature. 2021;595(7868):572\u20137. https:\/\/doi.org\/10.1038\/s41586-021-03653-6.","journal-title":"Nature"}],"updated-by":[{"DOI":"10.1007\/s40121-024-00998-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000}}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-023-00896-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-023-00896-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-023-00896-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T06:17:21Z","timestamp":1718432241000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-023-00896-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,16]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["896"],"URL":"https:\/\/doi.org\/10.1007\/s40121-023-00896-w","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40121-024-00998-z","asserted-by":"object"}]},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,16]]},"assertion":[{"value":"19 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40121-024-00998-z","URL":"https:\/\/doi.org\/10.1007\/s40121-024-00998-z","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Chen Mo, Zijing Yue, Ying Ma, Qing-Shuang Wang, Ren-Du Wen, Zheng Yao, Jia-Ping Yu, Wen-Rong Yao, Jian-Hui Zhang, Kun-Xue Hong, Yong Liu are employees of Jiangsu Recbio Technology Co., Ltd. All the other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"For the phase\u00a01 study, the study protocol and informed consent were approved by the Ethics Committee of the New Zealand Clinical Research. For the phase\u00a02 study, the study protocol and informed consent were approved by the Ethics Committee of St. Paul\u2019s Hospital, the Medical City Iloilo and the Health Centrum in Philippines. Informed consent was obtained from each subject before any study procedures were performed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}